Disease modifying therapies in multiple sclerosis

Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

D.S. Goodin, MD; E.M. Frohman, MD; G.P. Garmany, Jr., MD; J. Halper, MSN, ANP, FAAN; W.H. Likosky, MD; F.D. Lublin, MD; D.H. Silberberg, MD; W.H. Stuart, MD; and S. van den Noort, MD

Overview. Clinical types of MS. MS is a chronic recurrent inflammatory disorder of the CNS. The disease results in injury to the myelin sheaths, the oligodendrocytes, and, to a lesser extent, the axons and nerve cells themselves. The symptoms of MS vary, depending in part on the location of plaques within the CNS. Common symptoms include sensory disturbances in the limbs, optic nerve dysfunction, pyramidal tract dysfunction, bladder or bowel dysfunction, sexual dysfunction, ataxia, and diplopia.

Four different clinical courses of MS have been defined. The first, relapsing–remitting MS (RRMS), is characterized by self-limited attacks of neurologic dysfunction. These attacks develop acutely, evolving over days to weeks. Over the next several weeks to months, most patients experience a recovery of function that is often (but not always) complete. Between attacks the patient is neurologically and symptomatically stable. The second clinical course, secondary progressive MS (SPMS), begins as RRMS, but at some point the attack rate is reduced and the course becomes characterized by a steady deterioration in function unrelated to acute attacks. The third clinical type, primary progressive MS (PPMS), is characterized by a steady decline in function from the beginning without acute attacks. The fourth type, progressive–relapsing MS (PRMS), also begins with a progressive course although these patients also experience occasional attacks.

Outcome measures in MS clinical trials. Evaluation of the relative effectiveness of different therapies requires consideration of which outcome measure or measures are relevant to the goals of therapy. Clearly, the most important therapeutic aim of any disease-modifying treatment of MS is to prevent or postpone long-term disability. However, long-term disability in MS often evolves slowly over many years. Clinical trials, by contrast, study patients for only short periods of time (2 or 3 years) and, therefore, use only short-term outcome measures to assess efficacy. As a result, it is important to validate any short-term measure by its correlation with the actual patient outcome many years later. For a discussion of these issues, interested readers should consult the full-length assessment on the Neurology Web site at www.neurology.org.

Scope of this guideline. The purpose of this assessment is to consider the clinical utility of these disease-modifying agents including the anti-inflammatory, immunomodulatory, and immunosuppressive treatments that are currently available. Symptomatic and reparative therapies will not be considered.

Before considering the evidence from individual
trials, however, a few statistical and interpretational points are worth bearing in mind. First, although a p value of 0.05 is commonly taken as evidence of a therapeutic benefit to treatment, there is concern that this may be too liberal a standard. For example, the Type I error rate (i.e., the so-called alpha-error) reflects the likelihood of concluding incorrectly that a useless treatment is of value. Surprisingly, however, for an experimental observation with a p value of 0.05, the calculated (i.e., theoretically expected) minimum Type I error rate, for a two-tailed comparison, is actually 13%.7-10 For a one-tailed comparison, this minimum Type I error rate is actually 21%.7-10 Thus, if the aim is to reduce the Type I error rate to the nominal value of 5% for statistical significance (for a single comparison), using this type of analysis, the observed p value would need to be ≤0.01.7-10 Consequently, when evaluating the results from a particular trial, statistical observations between p = 0.01 and p = 0.05 should be regarded as marginal. This is especially true when the study under consideration reports multiple between-group statistical comparisons, because multiple comparisons markedly inflate the actual Type I error rate and require a much more stringent statistical adjustment.11-15 There is also concern about the Type II error rate of clinical trials (i.e., the so-called beta error), which reflects the likelihood of concluding incorrectly that a useful treatment is of no value.16 For example, one recent trial17 found that after 2 years of treatment, sustained disability progression was nonsignificantly reduced by 12%. Clearly, such a result cannot be used to reject a true 12% reduction in this measure, and, in fact, this nonsignificant observation is still compatible with an even more robust treatment effect.18 The issue is the statistical power (i.e., 1-beta) of the clinical trial to detect group differences and this, in turn, is related to the number of subjects studied.18 In this particular trial,17 the number of subjects studied (i.e., 251) provided insufficient power to detect a 12% change on this outcome. If a much larger number of subjects had been entered into the trial, and if the same magnitude and variability of the treatment effect had been obtained, this change would have been statistically significant. As a consequence of such difficulties, it is important to recognize that negative results from small clinical trials generally provide little assurance that a true treatment effect has not been missed. Second, because it is uncertain which outcome measures correlate best with future function, clinical trials that use a combination of outcome measures, including both clinical and confirmatory MRI measures, should be judged as stronger evidence than those that rely on only a single measure, especially when that measure is a subjective clinical score. Third, it is important to recognize that both the statistical significance of a finding and the magnitude of the treatment effect (i.e., the effect-size) provide important complementary information about the quality of the evidence. The statistical significance relates to the believability of a result, whereas the effect size relates to its clinical importance. Trials with large effects of marginal significance and trials with significant effects of marginal importance should both be judged as providing equivocal evidence. Fourth, it should be noted that treatments aimed at limiting future CNS injury would not be expected to cause an already disabled patient to improve dramatically, even though some patients may experience some clinical improvement based on intrinsic self-repair mechanisms. Consequently, reports of substantial improvement following the use of such agents should be viewed with caution.

A synopsis of the conclusions and recommendations for all the treatments considered is provided in the Summary. The actual analysis of the evidence (table), however, is provided here only for the immunomodulatory treatments. Readers interested in the analysis of the evidence for other therapies should consult the full-length assessment on the Neurology Web site at www.neurology.org.

Analysis of the evidence. Immunomodulatory treatments. Interferon beta. Clinical trial results. The multicenter study of IFN-beta-1b (Betaseron; Berlex Laboratories, Montville, NJ) in RRMS18-20 was randomized, double-blind, and placebo-controlled (Class I evidence). It included 372 patients with RRMS who had scores on the extended disability status scale (EDSS) ≤5.5 and who had experienced at least two attacks in the prior 2 years. Patients were randomized to receive placebo, low-dosage (1.6 million of International Units [MIU]; 50 µg), or high-dosage (8 MIU; 250 µg) IFN-beta-1b subcutaneously (SC) every other day for 2 years. After 2 years, compared with placebo, treatment with high-dosage IFN-beta-1b reduced the clinical relapse rate (<34%; p < 0.0001), which was the primary endpoint of the study. In addition, the MRI attack rate as measured by median number of T2 active lesions (<83%; p < 0.009) and the median volume of MRI T2 disease burden (<17.3%; p = 0.001) were reduced in the IFN-beta-1b arm compared with placebo-treated patients. The high dosage also resulted in a reduction in the confirmed 1-point EDSS progression rate, but this was not statistically significant (<29%; p = 0.16). This trial, however, did report a reduction in the unconfirmed 1-point EDSS worsening over 3 years of study (<31%; p = 0.043).

In summary, this trial provides (Class I) evidence that IFN-beta reduces the relapse rate (measured either clinically or by MRI) in patients with RRMS. The effect of treatment on measures of disease severity (i.e., MRI disease burden and disability progression) is less consistent. There was a robust effect of treatment on the MRI disease burden but no statistically significant effect on the measure of confirmed 1-point EDSS progression.

The IFN-beta-1a (Avonex; Biogen, Cambridge, MA) trial21-23 also was multicenter, randomized, and placebo-controlled (Class I evidence). It included 301
patients with RRMS who had an EDSS score of 1.0–3.5, and who had experienced at least two attacks in the 3 years prior to entering the study. Patients were treated either with placebo or IFNβ-1a, 6 MIU/wk (30 μg/wk), intramuscularly (IM) for 2 years. This trial was stopped earlier than originally designed, so only 57% (172 patients) completed the full 2 years on study medication. Compared with placebo, treatment with Avonex for 2 years produced a reduction in the confirmed 1-point EDSS progression rate (−37%; p = 0.02), which was the primary endpoint of the trial. In addition, the clinical attack rate (−18%; p = 0.04) and the MRI attack rate as measured by the median number of gadolinium enhancing lesions (−33%; p = 0.05) were reduced in the IFNβ-1a arm compared with placebo-treated patients. The total volume of T2 disease burden seen on MRI also was reduced compared with placebo, but this was not statistically significant (−6.7%; p = 0.36). This trial also found that the reduction in attack rate in the first year of therapy (−9.6%, not significant) was less than the reduction in patients who had completed 2 years of therapy (−32%; p = 0.002), suggesting that the full clinical benefits of IFNβ-1a therapy might be delayed for a year or more after the initiation of treatment.18,20,24,25 Nevertheless, the authors provide no statistical evidence of a difference between the 1-year and 2-year data, and, in addition, the other IFNβ trials in RRMS did not observe such a delay in therapeutic benefit.18,20,24,26,27 Most important, however, this subgroup of patients (who had a 32% reduction in attack rate over 2 years) had a similar reduction in attack rate (−29%) at the 1-year mark.25 Such an observation indicates that this particular subgroup of patients (i.e., the 2-year completers) is not representative of the study cohort as a whole. As a result of this anticipated bias, the validity of any separate analysis on this subgroup of patients is questionable. A re-analysis of the trial data (for the subgroup of 2-year completers only) using the “brain parenchymal fraction” to measure brain atrophy28 showed no statistically significant reduction in brain atrophy after 2 years of treatment (p = 0.30). A subgroup analysis did show a reduction of accumulated atrophy in the second year of treatment (p = 0.03). This latter observation, however, was only marginally significant and was the result of a post hoc analysis on a biased subset of the study population, and the reported p value was not adjusted for the three between-group statistical comparisons of brain parenchymal fraction presented in the article’s figure.28 Therefore, the validity of this observation is uncertain.

In summary, this trial provides (Class I) evidence that IFNβ-1a reduces the biologic activity of RRMS. Importantly, the results of this trial replicate, in general, the earlier IFNβ-1b trial for both clinical and MRI outcomes, although again the effect of treatment on attack rate measures was more consistent than for measures of disease severity. Thus, both clinical and MRI measures of attack rate were similarly improved at 2 years. In addition, there was a reduction in the confirmed 1-point EDSS progression rate, although there was no statistically significant concomitant benefit on either MRI disease burden or brain atrophy during the 2 years of study.
The IFNβ-1a (Rebif; Serono International SA, Geneva, Switzerland) trial was a similarly randomized, multicenter, double-blind, and placebo-controlled study (Class I evidence). A total of 560 patients with RRMS with an EDSS score ≤5.0 were entered. Only patients who had experienced 2 or more relapses in the prior 2 years were included. Patients were treated for 2 years with placebo or IFNβ-1a at dosages of either 22 μg (6 MIU) or 44 μg (12 MIU) SC three times weekly. After 2 years, there was a significant beneficial effect of treatment with either dose on both clinical and MRI outcome measures. Thus, compared with placebo, treatment with IFNβ-1a, 132 μg/wk (36 MIU/wk), reduced the clinical attack rate (−32%; p < 0.005), which was the primary endpoint of the trial. In addition, the MRI attack rate as measured by median number of T2 active lesions (−78%; p < 0.0001), the volume of white matter disease seen on T2-weighted MRI. Publication of the final results of this trial was pending. The reason for the apparently discrepant findings between these two trials of IFNβ-1b is not clear. Some observers have noted that the North American cohort of patients had significantly fewer attacks than their European counterparts, and that perhaps IFNβ is most effective in the relapsing phase of the illness. At the moment, however, such a notion is speculative.

The recently published trial of IFNβ-1a (Rebif) in SPMS also failed to find a statistically significant reduction in the confirmed 1-point EDSS progression rate (the primary endpoint of the trial). Like the IFNb-1b (Betaseron) trial, however, this trial also found significant reductions in the clinical attack rate, the MRI attack rate, and the volume of white matter disease found on T2-weighted MRI. Also, when the results of this trial were reanalyzed by separating patients into those with and those without attacks, a benefit to treatment on the confirmed 1-point EDSS progression rate was noted (p = 0.027) in patients with relapses. The validity of such a re-analysis of the data is clearly open to question, but nevertheless might be taken as weak support for the speculation (noted above) that IFNβ is more effective in patients with SPMS who continue to experience relapses.

Another recent (Class I) study of IFNβ-1a (Avonex) in the treatment of SPMS has been reported in preliminary form. Using the MS functional composite as the primary outcome, this trial found that, compared with placebo, treatment with IFNβ-1a, 60 μg/wk, IM was beneficial over a 2-year period (p = 0.03). This study, however, did not find any concomitant benefit on the outcome of confirmed 1-point EDSS progression. Moreover, the benefit seen on the MS functional composite outcome was due primarily to the results from the Nine-Hole Peg Test portion of the composite score. The reported benefit of therapy in this trial, therefore, is of uncertain reliability.

Two recently completed trials of IFNβ-1a (Avonex and Rebif) in patients at high risk of developing MS have shown that early treatment significantly slows...
the subsequent rate of conversion to clinically definite MS (CDMS). The IFNβ-1a (Avonex) trial was a multicenter, randomized, placebo-controlled trial involving 383 patients who were followed for up to 3 years (Class I evidence). Patients needed to have just experienced their first clinically isolated (monosymptomatic) CNS event consisting of an optic neuritis, a spinal cord syndrome, or a brainstem/cerebellar syndrome. Patients also had to have an abnormal brain MRI defined as two or more clinically silent lesions (≥3 mm) on T2-weighted MRI scans, at least one of which needed to be ovoid in appearance or periventricular in location. Patients initially were treated with intravenous methylprednisolone, 1 g/d for 3 days, followed by a course of oral prednisone, 1 mg/kg/d for 15 days. Patients subsequently received either IFNβ-1a (30 μg/wk, IM) or placebo throughout the study. Using a Cox proportional hazard model, the relative risk of developing CDMS in the treated group was 0.56 (p = 0.002), indicating a 44% decrease in the rate of conversion to MS after administration of IFNβ-1a, which was the primary endpoint of the trial. MRI measures also demonstrated a robust treatment effect. Thus, at 18 months, the number of new lesions (−57%; p < 0.0001), the percentage change in the T2 lesion volume (−14%; p = 0.0004), and the number of enhancing lesions (−67%; p < 0.0001) all were reduced using IFNβ-1a when compared with placebo. The IFNβ-1a (Rebif) trial also was a multicenter randomized trial (Class I evidence) involving 309 patients who had experienced their first clinical episode suggestive of demyelinating disease (either mono- or polysymptomatic) and who were followed for 2 years thereafter. Patients received either IFNβ-1a (22 μg/wk, SC) or placebo throughout the study. The proportion of patients converting to CDMS was less in the treated group compared with placebo (−24%; p = 0.047). In addition, the median number of T2 active lesions seen on MRI also was reduced in the treated compared with placebo patients (p < 0.001). The T2 disease burden also was reduced in the treated arm compared with placebo in both year 1 and year 2 of the trial (p = 0.006 and p = 0.002, respectively).

These trials, therefore, provide (Class I) evidence that treatment with IFNβ-1a delays the development of CDMS in patients at high risk for this outcome. Such a result is hardly surprising. Indeed, any treatment for RRMS that can delay the time between attacks 2 and 3 or between attacks 3 and 4 (i.e., any treatment that reduces the attack rate) also would be expected to delay the time between attacks 1 and 2. These studies do not, however, provide evidence that the ultimate development of CDMS is prevented by such treatment. Neither do they provide any evidence that early treatment affects long-term disability outcome.

Effects of IFNβ type, route of administration, and dose on clinical outcome. The total dosage of IFNβ used in the different clinical trials of both RRMS and SPMS has varied considerably between studies and it is important to consider the evidence that there may be a dose-response curve in the use of IFNβ for the management of patients with MS. Because the pharmaceutical companies that manufacture Avonex, Betaseron, and Rebif use slightly different assays to measure IFNβ activity, the MIU scales reported in the different papers are not directly comparable between publications. Nevertheless, because Avonex and Rebif are both forms of IFNβ-1a, they can be compared on a microgram for microgram basis. Also, the conversion of IFNβ-1a to IFNβ-1b doses can be calculated using published data, with the result that 6 MIU Avonex (30 μg) is equivalent to approximately 7-9 MIU Betaseron (220-280 μg).

IFNβ induces the expression of many gene products and interferon-specific markers, including 2',5'-oligoadenylate synthetase (2',5'-OAS), neopterin, tryptophan, β2-microglobulin, and human Mx protein. These markers reflect a range of biologic activities of IFNβ, including MHC Class-I gene expression, antiviral and antiproliferative actions, and macrophage activation. These markers have been used as indicators of the biologic activity of IFNβ. The relative dose of the different preparations also can be assessed from another recent publication in which antiviral protein (MxA) stimulation was studied in the untreated blood from 10 healthy volunteer subjects. In this study, in vitro stimulation of peripheral blood with all three agents (Avonex, Betaseron, and Rebif) resulted in a dose-dependent increase in MxA levels that was roughly equivalent for each agent on a MIU for MIU basis using the published MIU values.

One study initially suggested that IM administration of IFNβ-1a caused a substantially greater area under the concentration-time curve for IFNβ activity in the serum compared with SC administration. By contrast, a different study compared the effects of IFNβ-1a given SC and IM and IFNβ-1b given SC on neopterin, human Mx protein, and 2',5'-OAS in 75 healthy volunteer subjects. IFNβ-1a was administered at doses of 1, 3, 6, 9, and 12 MIU and IFNβ-1b at doses of 2, 4, 8, 12, and 16 MIU; each patient in the study received a single dose. The results showed that the production of all three markers was induced in a dose-dependent manner for both IFNβ-1a and IFNβ-1b. Moreover, this study found no differences in any of these biologic effects between the two types of IFNβ or between the different routes of administration. Similar results have been found by other investigators. Thus, the balance of the evidence favors the view that the route of IFNβ administration is not of clinical importance.

The previously cited study also examined the levels of MxA in the peripheral blood in 237 patients with CDMS after administration of IFNβ. There were 78 patients receiving IFNβ-1b (Betaseron) at a dosage of 8 MIU (250 μg) every other day; 71 patients receiving IFNβ-1a (Rebif) at a dosage of 6 MIU (22 μg) SC either weekly or three times weekly; and
21 patients receiving IFNβ-1a (Avonex) at a dosage of 6 MIU (30 μg) IM once weekly. The level of MxA was 2.29 ng/10^5 peripheral blood lymphocytes (PBL) in the Betaseron-treated patients, 1.00 ng/10^5 peripheral blood lymphocytes in the Rebif-treated patients, and 0.57 ng/10^5 peripheral blood lymphocytes in the Avonex-treated patients. In summary, the results of this trial suggest that increasing the total weekly IFNβ dose is associated with an increasing biologic effect (Class II evidence). However, whether the measured biologic effect (on MxA levels) is relevant to the effect of IFNβ on disease activity, cannot be assessed from this trial.

The results of the pivotal clinical trials of IFNβ in RRMS also suggest a dose-response curve.

Thus, in general, when comparing the different findings of these trials, both the magnitude of the reported effects on clinical and MRI outcomes, as well as their statistical significance, seem to be greater with increasing dosages of IFNβ. Nevertheless, because of differences in trial design, differences in the MS populations studied, and the fact that the results were obtained in independent clinical trials, this observation can only be considered as weak (Class III) evidence of a dose response.

The findings of the two placebo-controlled Class I IFNβ studies that investigated different doses of IFNβ provide mixed results.

Thus, in the Betaseron trial,18-20 treatment with low-dose IFNβ-1b (5.6 MIU/wk) was significantly better than placebo (p < 0.01) on the measure of clinical attack rate over the first 2 years, although it was significantly less effective on this measure (p < 0.0086) than the higher dose of 28 MIU/wk. Trends in favor of the higher dose also were seen on other outcome measures, although no other statistically significant dose effects were noted. In the Rebif trial,22,26 both doses were highly effective, although the high-dose arm did better on each clinical and MRI outcome measure than the low-dose (18 MIU/wk) arm. With the exception of the outcome of T2 active lesions (p = 0.0003 comparing low dose to high dose), however, there were no statistical differences between the two doses at the 2-year time point. Thus, although based on high-quality (Class I) studies, the evidence in favor of a dose response provided by these trials is only equivocal.

The Rebif trial was continued for an additional 2 years.42 Placebo-treated patients during the first 2 years were re-randomized in a double-blind fashion to receive IFNβ-1a, either 66 μg or 132 μg weekly, in divided doses. After 4 years, a dose-response relationship was seen for some clinical and MRI outcomes but not for others. Thus, the high dose was more effective than the low dose (p < 0.05) at reducing the relapse rate during years 3 and 4, prolonging the time to second relapse, and increasing the percentage of relapse free patients. Similarly, treatment with high dose IFNβ-1a reduced the MRI disease burden and T2 lesion activity (p < 0.001) compared with low dose (Class I evidence). By contrast, the high-dose group was not statistically better than the low-dose group on the outcomes of attack rate measured over years 1 to 4 (−12%; p = 0.069), or the time to confirmed 1-point EDSS progression (+17%; p = 0.33). In addition, an analysis (Class III evidence) of the combined results of the Avonex and Rebif trials suggested that IFNβ-1a has increasing clinical efficacy (as measured by the clinical attack rate at 1 year) between the doses of 22 and 132 μg weekly.43 By contrast, the results of the SPECTRIMS trial of IFNβ-1a in SPMS demonstrated no difference between 66 and 132 μg weekly with respect to any clinical outcome measure relating to relapse rate.41

The results of a multicenter, double-blind, dose-comparison trial of IFNβ-1a (Avonex) recently has been reported.43 This trial included 678 patients with RRMS who received IFNβ-1a, either 30 μg/wk or 60 μg/wk, IM once weekly for a period of at least 3 years (Class I evidence). There was no difference in outcome between the two dosage groups with respect to EDSS progression, relapse rate, gadolinium (Gd)-enhancing lesions, T2 lesion burden, or brain atrophy over the course of the trial.43 This trial thus provides Class I evidence that 60 μg IFNβ-1a (IM) once weekly provides no additional benefit over 3 years of therapy compared with 30 μg (IM) once weekly over the same period.

Recently, the preliminary results of two head-to-head comparison trials of different IFNβ preparations have been reported.44,45 The first was a 2-year, open-label, randomized trial of IFNβ-1b (Betaseron; 28 MIU/wk, SC) compared with IFNβ-1a (Avonex; 30 μg/wk, IM) in 188 patients with RRMS. Only the data after 1 year of therapy have been presented. This trial found a greater clinical benefit in the higher dose (more frequently administered) IFNβ-1b group, both on clinical outcomes (i.e., relapse free status and sustained progression) and on MRI outcomes (i.e., new T2 lesions or Gd-enhancing lesions), compared with the IFNβ-1a group. The evaluating physician, however, was unblinded for clinical outcomes so that the clinical observations from this trial represent only Class III evidence. MRI, by contrast, was assessed blindly so that these observations represent Class I evidence. The second was a randomized, 1-year, open-label trial comparing high-dose, more frequently administered, IFNβ-1a (Rebif; 132 μg/wk, SC) to low-dose, once weekly, IFNβ-1a (Avonex; 30 μg/wk, IM) in 677 patients with RRMS. Both clinical and MRI outcome measures were assessed in a blinded fashion (Class I evidence). Only data after 6 months of therapy and only outcome measures relating to relapse rate have been presented. At 6 months, the high-dose (more frequently administered) IFNβ-treated group was statistically superior to the low-dose group on both clinical and MRI outcome measures related to attack rate. These clinical outcomes included the odds of being attack free, the attack rate, and the time to first exacerbation and steroid use, whereas the MRI outcomes included the odds of not having new T1 or T2 lesions,
the total number of new lesions, and the cumulative number of new active lesions. The design of these trials confounds the effect of IFNβ dose with the effect of the frequency of IFNβ administration because, in each, both parameters differed between the two treatment arms. Nevertheless, these trials provide (Class I) evidence that either the dose, or the frequency of IFNβ administration, or both, significantly influence the short-term outcome in patients with RRMS. The final results from both trials currently are not available. Nevertheless, these final results are critically important and it will be necessary to assess whether these apparent short-term advantages to high-dose (more frequent) IFNβ therapy are sustained over time.

Neutralizing antibodies to IFNβ The rate of neutralizing antibody (NAb) production is probably less with IFNβ-1a treatment than with IFNβ-1b treatment, and the presence of NAb may be associated with a reduction in clinical effectiveness of IFNβ treatment. The existing data are, however, ambiguous in this regard, and the clinical utility of measuring NAb in an individual on IFNβ therapy is uncertain. Readers interested in discussion of this issue should consult the full-length assessment on the Neurology Web site at www.neurology.org.

Glatiramer acetate. Glatiramer acetate (Copaxone; Teva-Marion Partners, Kansas City, MO) is a random polypeptide made up of four amino acids (L-glutamic acid, L-lysine, L-alanine, and L-tyrosine) in a specific molar ratio (1.4, 3.4, 4.2, and 1.0, respectively). The mechanism of action is not known but may relate to a number of immunologic effects such as the induction of antigen-specific suppressor T cells, inhibition of antigen presentation, displacing bound myelin basic protein (MBP), or causing an immune deviation in CD4+ T cells from a Th1 to a Th2 phenotype.46-48

The results of a large multicenter, randomized, double-blind, placebo-controlled trial of glatiramer acetate17,49 initially were reported in 1995. This trial involved 251 patients with RRMS who had an EDSS score ≤5.0 and who had experienced two or more relapses in the 2 years before entering the study. Patients received either placebo or 20 mg glatiramer acetate SC daily for up to 3 years. This trial found that treatment with glatiramer acetate significantly reduced the clinical attack rate over a 2-year period (−29%; p = 0.007), which was the primary endpoint of the study. It also reduced the confirmed 1-point EDSS progression rate, although this change was not statistically significant (−12%). This trial also reported a reduction in the unconfirmed 1-point EDSS worsening over the first 2 years of the study (−28%; p = 0.037). Also, in a secondary analysis of data from the extension phase of this trial,23 after excluding determinations made during acute attacks, these authors reported a significant reduction in the unconfirmed 1.5 point EDSS progression rate over 3 years in the treated patients compared with control subjects (−48%; p = 0.004) using survival analysis methods. This last analysis, however, is of uncertain reliability. This outcome has not been used by other investigators, and, moreover, this particular outcome was arrived at through post hoc exploration of the data; thus, the observation is of uncertain validity. No MRI outcomes were determined as part of this trial. A second short-duration European/Canadian trial, was undertaken to look specifically at MRI measures.50 This was a placebo-controlled trial and involved 249 patients with RRMS who were randomized to receive either placebo or 20 mg glatiramer acetate SC daily for 9 months (Class I evidence). Patients, at entry, had to have an EDSS score of 0–5.0, they had to have experienced at least 1 clinical attack in the previous 2 years, and they had to have a Gd-enhancing lesion on their screening brain MRI. This trial reported that, compared with placebo, the treated group had a reduction in the total number of enhancing lesions (−35%; p = 0.001), which was the primary endpoint of the trial. This treatment effect, however, was delayed until 6 months after initiation of treatment. Treated patients also had a reduction in the clinical attack rate (−33%; p = 0.012) and a reduction in the median change in T2 burden of disease (−8.3%; p = 0.0011) compared with placebo. EDSS change over the course of the trial was minimal and was not different between the treatment and placebo groups.50

An earlier pilot trial (Class I) of glatiramer acetate at comparable dosages51 also reported a reduction in both the clinical attack rate (−76%; p < 0.001) and the confirmed 1-point EDSS progression rate (−60%; p = 0.05). MRI outcomes were also not assessed in this pilot trial. Another early pilot trial (Class I) of glatiramer acetate in the treatment of chronic progressive MS (including both PPMS and SPMS), reported a reduction in new lesions with glatiramer acetate (30 mg/d, SC) compared with placebo (−31%) although this difference was not statistically significant.52

Recently, experience with the extended use of glatiramer acetate over a 6-year period has been reported.53 This trial reports on the experience following 152 patients with RRMS who were initially enrolled in the placebo-controlled randomized trial17,49 and who continued to be followed after the breaking of the blind. All patients were on active drug during the follow-up interval and were compared with previously published natural history controls (Class III evidence). The authors reported stabilization of the EDSS score and a marked reduction in the clinical attack rate during follow-up. However, with a 40% dropout rate (compared with the number who were initially enrolled in the randomized trial), there are concerns that the cohort might be self-selected and, therefore, that the study may be biased in favor of a treatment effect. For example, the annual attack rate during the double-blind phase in patients who elected to continue on treatment was significantly less (p < 0.001) than in patients who decided not to continue (0.78 and 1.23
attacks/y, respectively). Similarly, there was a significant difference ($p = 0.003$) in the percentage of patients who had deteriorated by 1.5 EDSS points during the double-blind phase between those who elected to continue treatment (40%) and those who did not (62%). This cohort represents the longest continuous follow up of a group of treated MS patients for any of the currently available therapies. However, without a concurrent control group for comparison and given the limitations discussed above, it is difficult to know how best to use these data.

Although MRI was not part of the original Phase III clinical trial of glatiramer acetate, the authors recently reported the results of follow-up MRI in 135 of the 147 patients who remained in the long-term open-label follow-up cohort as of January 1999. In those patients who were initially on placebo, MRI were obtained an average of 4 years after being switched to active drug. By contrast, in those patients on active treatment from the beginning of the trial, MRI were obtained an average of 6.7 years after initiation of glatiramer acetate. Outcome was assessed by comparing different MRI parameters (including a composite MRI measure) between the two groups. The most significant difference reported between groups was a reduction in the percentage of Gd enhancement in the patients on glatiramer acetate from the beginning compared with patients originally on placebo (18.8% and 36.4%, respectively; $p = 0.02$). Taken at face value, this observation would suggest that the full benefit of glatiramer acetate therapy in reducing Gd enhancement (a phenomenon that only lasts about 3 months) is delayed for 4 or more years after the initiation of treatment. However, there are several reasons to doubt such an explanation. First, no comparable delay is suggested by the clinical data where the two groups had very similar attack rates within a year of when placebo-treated patients had been switched over to active therapy.

A recent study reported the results of a prospective 1-year, open-label, nonrandomized trial of once weekly IFNβ-1a (Avonex; 30 µg/wk), IFNβ-1b (Betaferon; 28 MIU/wk), glatiramer acetate (Copaxone; 20 mg/day), or no treatment in the management of 156 patients with RRMS. These authors reported that, compared with no treatment, clinical relapse rate was reduced in all three active treatment groups, although this reduction was statistically significant only for the IFNβ-1b–treated and glatiramer acetate–treated groups ($p \leq 0.003$), suggesting that these two preparations were more clinically effective than IFNβ-1a, at least at the dose and route of administration used in this study. This trial, however, used a nonrandomized design and a nonblinded assessment of outcome; therefore, these data represent only weak (Class III) evidence in support of this conclusion.

**Summary**

**Glucocorticoids:**

1. On the basis of several consistent Class I studies, glucocorticoid treatment has been demonstrated to have a short-term benefit on the speed of functional recovery in patients with acute attacks of MS. It is appropriate, therefore, to consider for treatment with glucocorticoids any patient with an acute attack of MS (Type A recommendation).

2. There does not appear, however, to be any long-term functional benefit after the brief use of glucocorticoids in this clinical setting (Type B recommendation).

3. Currently, there is not compelling evidence to indicate that the clinical benefits are influenced by the route of glucocorticoid administration, the particular glucocorticoid prescribed, or the dosage of glucocorticoid, at least at the doses that have been studied to date (Type C recommendation).

4. On the basis of a single Class II study, it is considered possible that regular pulse glucocorticoids may be useful in the long-term management of patients with RRMS (Type C recommendation).

**Interferon beta:**

1. On the basis of several consistent Class I studies, IFNβ has been demonstrated to reduce the attack rate (whether measured clinically or by MRI) in patients with MS or with clinically isolated syndromes who are at high risk for developing MS (Type A recommendation). Treatment of MS with IFNβ produces a beneficial effect on MRI measures of disease severity such as T2 disease burden and probably also slows sustained disability progression (Type B recommendation).

2. As a result, it is appropriate to consider IFNβ for treatment in any patient who is at high risk for developing CDMS, or who already has either RRMS or SPMS and is still experiencing relapses (Type A recommendation). The effectiveness of IFNβ in patients with SPMS but without relapses is uncertain (Type U recommendation).

3. It is possible that certain populations of MS patients (e.g., those with more attacks or at earlier disease stages) may be better candidates for therapy than others, although, at the moment, there is insufficient evidence regarding these issues (Type U Recommendation).

4. On the basis of Class I and II studies and several pieces of consistent Class III evidence, IFNβ is probably not of clinical importance, at least with regard to efficacy (Type B recommendation). The side-effect profile, however, does differ between routes of administration. There is no known clinical difference between the different types of IFNβ, although this has not been thoroughly studied (Type U recommendation).

5. On the basis of several Class II studies, the route of administration of IFNβ is probably not of clinical importance, at least with regard to efficacy (Type B recommendation). The side-effect profile, however, does differ between routes of administration. There is no known clinical difference between the different types of IFNβ, although this has not been thoroughly studied (Type U recommendation).

6. On the basis of several Class I studies, treatment of patients with MS with IFNβ is associated with the production of NAb (Type A recommendation). The rate of NAb production, however, is probably less with IFNβ-1a treatment than with IFNβ-1b treatment (Type B recommendation). The biological effect of NAb is unclear, although the presence may be associated with a reduction in clinical effectiveness of IFNβ treatment (Type C recommendation). Whether there is a difference in immunogenicity between subcutaneous and intra-
muscular routes of administration is unknown (Type U recommendation). The clinical utility of measuring NAb in an individual on IFNβ therapy is uncertain (Type U recommendation).

**Glatiramer acetate:**
1. On the basis of Class I evidence, glatiramer acetate has been demonstrated to reduce the attack rate (whether measured clinically or by MRI) in patients with RRMS (Type A recommendation). Treatment with glatiramer acetate produces a beneficial effect on MRI measures of disease severity, such as T2 disease burden, and possibly also slows sustained disability progression in patients with RRMS (Type C recommendation).
2. As a result, it is appropriate to consider glatiramer acetate for treatment in any patient who has RRMS (Type A recommendation). Although it may be that glatiramer acetate also is helpful in patients with progressive disease, there is no convincing evidence to support this hypothesis (Type U Recommendation).

**Cyclophosphamide:**
1. Based on consistent Class I evidence, pulse cyclophosphamide treatment does not seem to alter the course of progressive MS (Type B recommendation).
2. Based on a single Class III study, it is possible that younger patients with progressive MS might derive some benefit from pulse plus booster cyclophosphamide treatment (Type U recommendation).

**Methotrexate:**
1. Based on limited and somewhat ambiguous Class I evidence from a single trial, it is considered possible that methotrexate favorably alters the disease course in patients with progressive MS (Type C recommendation).

**Azathioprine:**
1. On the basis of several, but somewhat conflicting, Class I and II studies, it is considered possible that azathioprine reduces the relapse rate in patients with MS (Type C recommendation).
2. Its effect on disability progression has not been demonstrated (Type U recommendation).

**Cladribine:**
1. On the basis of consistent Class I evidence, it is concluded that cladribine reduces Gd enhancement in patients with both relapsing and progressive forms of MS (Type A recommendation).
2. Cladribine treatment does not, however, appear to alter favorably the course of the disease, either in terms of attack rate or disease progression (Type C recommendation).

**Cyclosporine:**
1. Based on this Class I study, it is considered possible that cyclosporine provides some therapeutic benefit in progressive MS (Type C recommendation).
2. However, the frequent occurrence of adverse reactions to treatment, especially nephrotoxicity, together with the small magnitude of the potential benefit, makes the risk/benefit of this therapeutic approach unacceptable (Type B recommendation).

**Mitoxantrone:**
1. On the basis of generally consistent Class II and III studies, it is concluded that mitoxantrone probably reduces the attack rate in patients with relapsing forms of MS (Type B recommendation). The potential toxicity of mitoxantrone, however, may outweigh the clinical benefits early in the course of disease.
2. On the basis of several Class II and III observations, it is considered possible that mitoxantrone has a beneficial effect on disease progression in MS, although, at the moment, this clinical benefit has not been established (Type C recommendation).

**Intravenous immunoglobulin:**
1. The studies of intravenous immunoglobulin (IVIg), to date, have generally involved small numbers of patients, have lacked complete data on clinical and MRI outcomes, or have used methods that have been questioned. It is, therefore, only possible that IVIg reduces the attack rate in RRMS (Type C recommendation).
2. The current evidence suggests that IVIg is of little benefit with regard to slowing disease progression (Type C recommendation).

**Plasma exchange:**
1. On the basis of consistent Class I, II, and III studies, plasma exchange is of little or no value in the treatment of progressive MS (Type A recommendation).
2. On the basis of a single small Class I study, it is considered possible that plasma exchange may be helpful in the treatment of severe acute episodes of demyelination in previously nondisabled individuals (Type C recommendation).

**Sulfasalazine:**
1. Based on a single Class I study, it is concluded that treatment of MS with sulfasalazine provides no therapeutic benefit in MS (Type B recommendation).

**References**


Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
Neurology 2002;58;169-178

This information is current as of August 19, 2010

<table>
<thead>
<tr>
<th>Updated Information</th>
<th>including high-resolution figures, can be found at: <a href="http://www.neurology.org/cgi/content/full/58/2/169">http://www.neurology.org/cgi/content/full/58/2/169</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://www.neurology.org/cgi/content/full/58/2/169/DC3">http://www.neurology.org/cgi/content/full/58/2/169/DC3</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/misc/Permissions.shtml">http://www.neurology.org/misc/Permissions.shtml</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://www.neurology.org/misc/reprints.shtml">http://www.neurology.org/misc/reprints.shtml</a></td>
</tr>
</tbody>
</table>
Cerebral Vasospasm
edited by R. Loch Macdonald and Bryce Weir, 518 pp., ill., San Diego, CA, Academic Press, 2001, $149.95

Cerebral Vasospasm, authored by R. Loch Macdonald and Bryce Weir, is an important and welcome addition to the published works on vasospasm. It consists of 12 chapters and 518 pages. This well-illustrated work includes eight color plates at the center of the book. The first chapter describes the historical aspects with respect to the pathology and radiology as well as medical, surgical, and physiologic aspects of the disease. The second chapter, "Epidemiology," provides a thorough review (123 references) of epidemiologic aspects including prognostic factors for spasm.

The third chapter, "Hematology," describes structure, function, and metabolism of cellular blood products and reviews coagulation; the fourth chapter, "Pathology and Pathogenesis," provides amply illustrated pages with electronmicroscopic pictures of normal and pathologic blood vessels. It also documents changes in arteries, CSF, and adjacent tissues after vasospasm. A description of angiographic CT, transcranial Doppler, MRI, PET scan, SPECT scan, and Xenon CT studies after vasospasm is provided in Chapter 5.

Chapter 6, "Pharmacology," is extremely detailed and reviews almost every putative causative agent in vasospasm, including neurogenic factors, biogenic amines, and free radicals. An impressive 689 studies are referenced. The detail provided in Chapter 7, "Vascular Smooth Muscle," rivals most definitive physiologic texts on the subject. "The Medical Aspects of Vasospasm" follows and reviews clinical aspects of vasospasm including diagnosis, prophylaxis, and management of delayed ischemic deficits and therapy. The authors liberally illustrate their rationale behind Triple H therapy and extensively review the pertinent studies relating to Triple H therapy and angioplasty.

The next chapter reviews uncommon causes of vasospasm as well as vasospasm after head injury, infection, and eclampsia. Chapter 10 illustrates surgical aspects of vasospasm including clot removal, cisternal drainage, and the timing of surgery with respect to vasospasm. Animal models have served an important role in the attempt to understand the physiologic mechanisms underlying this disease and Chapter 11 describes the models that have been published to date. The last chapter describes some of the molecular biologic changes in the regulation of smooth muscle contraction and relaxation. It also describes changes in genes that may alter vasospasm and provides a glimpse of some of the future therapeutic possibilities in the fight against this devastating disease.

This text should be extremely useful to anyone remotely interested in this incompletely understood problem that results after subarachnoid hemorrhage. It is a unique work that effectively reviews in detail all significant aspects of the disease. I do not think that the final sentence in the foreword—"This book is the single most important factor in finding a remedy for vasospasm"—is overstated.

Cargill Alleyne, MD

Copyright © 2002 by AAN Enterprises, Inc.

Brain's Diseases of the Nervous System

Dr. Russell Brain originally published "Brain's Diseases of the Nervous System" in 1953 and remained the sole author of numerous further additional editions up to the seventh, when he was joined by Prof. John Walton. Brain died in 1966 and the next two editions were written by Dr. Walton. The book, edited by Walton, became multi-authored in 1993 and it is now edited by Michael Donaghy, who has revised this edition with the aid of 14 British authors.

The book consists of seven sections starting with an introduction that discusses clinical diagnosis and investigation, with a review of headache, pediatric neurology, toxic and environmental disorders, disability, rehabilitation, and spinal injury, as well as developmental degeneration and regeneration of the nervous system with neuroimmunology tackled on. There follow sections on the disorders of the special senses, peripheral neurology, structural disorders of the neuraxis, seizures and alteration of consciousness, and infections. Stroke, demyelinating disorders, and degenerative disorders are lumped together as a separate section for no apparent reason. Poor planning.

Limiting the author list to 14 implies that each will write more than one chapter. This results in some unevenness, where a superb review of a specific subject (presumably the author's specialty) will be followed by a comparatively cursory treatment of another topic. Yet the book provides a good catalog of neurologic disease with excellent references. The chapters on epilepsy in adults, neuro-ophthalmology, infections, movement disorders, cerebellar ataxia, and MS are excellent reviews and would stand on their own anywhere—others are adequate. Each section follows a similar plan of introduction before getting down to business—this results in some repetition within chapters.

This is a large, heavy book. It will find its place on the bookshelf and be used mainly for reference; it would be hard to read it cover to cover (as I did one of the early editions when I was a medical student and subsequently a registrar in neurology). Its target audience will therefore be practicing neurologists and neurologists in training and the language used assumes some familiarity with the subject.

The authors have worked hard to produce an up-to-date catalog and review of contemporary neurology, but as with all textbooks it is possible to carp at some of the statements and the way that subjects are presented. The distinction between "primary" and "secondary" headache is not spelled out and so-called "red flags" are not discussed as such, an important omission for a text targeted to neurologists in training. The description of bladder dysfunction made heavy going—a drawing would have helped.

Some of the drugs named are either not available or go under another name in the United States (pethidine = meperidine, Demerol). In the discussion of diabetic nonketotic hyperglycemia, no mention is made of epilepsia partialis continua. Pituitary apoplexy is mentioned without delineation of the cardinal signs of low blood pressure and slow pulse. In the discussion of confusion, attention (immediate recall) is lumped as a memory dysfunction. The Alzheimer genetics diagrams, although correct, are largely incomprehensible without explanation and must have come from a slide presentation. In the stroke section the author makes the statement "in acute stroke nothing makes much difference." The genetics of familial spastic paraplegia is dismissed as unknown. In the discussion of essential tremor mention is made of a "unit of alcohol"—I wonder how big a unit is?

Despite a worthy effort, the authors have been let down by the publisher. This is a clothbound hardcover book. One of my residents looked at it 2 weeks after delivery and thought it was ancient and worn. A few pages fell out. Many of the illustrations look like slides that the authors submitted—they are largely illegible, and many of the photographs are so dark as not to be practicable. A series of colored plates appears out of the blue in the middle of the epilepsy chapter and has nothing to do with the subject. Typographic errors are not infrequent. The photograph meant to demonstrate asterixis is a bit odd—the subject is in French cuffs with cufflinks!

The reservations about content are minor and do not detract at all from the contemporary review. This book may be one of the last such presentations to be produced in print. Current digitized versions of neurology textbooks are more comprehensive and fit on a compact disk; if nothing else, they are lighter yet bigger. The competition is fierce!

Michael Ronthal, MBBCCh, FRCP, FRCPPE

Copyright © 2002 by AAN Enterprises, Inc.
Clinical Neurophysiology of the Vestibular System, 3rd Edition


Clinical Neurophysiology of the Vestibular System is again authored by Drs. Baloh and Honrubia. This 3rd edition builds upon a strong foundation established in earlier editions by expanding the material on physical examination and laboratory assessment of the dizzy patient and adding material concerning pharmacotherapy and vestibular rehabilitation for the symptomatic treatment of vestibular disorders. The book is very informative, and should appeal to any clinician who regularly sees patients with dizziness and dysequilibrium. Because of its comprehensive and scholarly approach, the book will be valuable to physicians in training who desire an accurate and well-referenced resource regarding vestibular disorders.

The book is 408 pages long and contains 53 tables and 143 figures, which appropriately summarize and enhance the text. The book is divided into four parts, including I. Anatomy and Physiology of the Vestibular System, II. Evaluation of the Dizzy Patient, III. Diagnosis and Management of Common Neurologic Disorders, and IV. Symptomatic Treatment of Vertigo. Part I provides necessary background information. Part II discusses the practical issues of the history, physical examination, and laboratory assessment of the dizzy patient. Part III discusses both common and uncommon neurologic disorders, providing the reader with a comprehensive and contemporary view of the field. Part IV is a brief discussion of treatment issues that pertain to the management of vestibular disorders in general.

The authors are somewhat selective in their choice of approach and their choice of references. This is especially the case for the more controversial issues in the field. In this way, the authors subtly provide the reader with the implicit judgments of two experienced clinicians.

The organization of the book may create a challenge, especially for the novice. For example, in Chapter 4, “The History of the Dizzy Patient,” the authors discuss the management of patients with specific types of complaints independent of a definitive diagnosis. They discuss the management of specific disorders in Part III, and then devote the entirety of Part IV to “Symptomatic Treatment of Vertigo.” The advantage of such an approach is that treatment issues are discussed in different contexts. The disadvantage is that similar information is found in several different places. Another organizational challenge for the reader concerns Chapters 8 through 17, wherein the authors discuss many specific neurologic disorders along the lines of the traditional disease classifications of infectious, immune, vascular, neoplastic, traumatic, toxic/metabolic, and developmental/genetic but discuss separately positional vertigo, Meniere syndrome, and migraine. Despite the organizational challenges that this book may present to the reader, this latest edition of Clinical Neurophysiology of the Vestibular System represents the definitive text in the field of otoneurology.

*Joseph Furman, MD*

Copyright © 2002 by the AAN Enterprises, Inc.
Correction

Disease modifying therapies in multiple sclerosis

In the article “Disease modifying therapies in multiple sclerosis” (Neurology 2002;58:169), the members of the DMT committee who were responsible for the document were inadvertently omitted. These were: Frohman EM and van den Noort S (co-chairs), Garmany GP, Goodin DS, Halper J, Likosky WH, Lublin FD, Silberberg DH, and Stuart WH.

In addition, the following disclosure statement was omitted: Several members of the author panel for the DMT document have participated (or are currently participating) in industry-sponsored clinical trials in multiple sclerosis. The sponsoring pharmaceutical companies for these trials have included (or do include) Ares-Serono, Berlex Laboratories, Biogen, Immunex, and Teva-Marion Partners. Many panel members have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies. In addition, the clinical operations (nursing and patient care services) of the different MS Centers at which several panel members work have been supported by non-restricted grants from one or more of these companies. The authors apologize for these errors.